Pharmacokinetics and Pharmacodynamics of Aerosolized Antibacterial Agents in Chronically Infected Cystic Fibrosis Patients

Interspecific Small Molecule Interactions between Clinical Isolates of Pseudomonas aeruginosa and Staphylococcus aureus from Adult Cystic Fibrosis Patients

(2014) Alexandre Fugère et al.   PLoS One

Cystic Fibrosis Pulmonary Guidelines

(2013) Peter J. Mogayzel et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Pharmacokinetics and Pharmacodynamics of Once-Daily Administration of Intravenous Tobramycin in Adult Patients with Cystic Fibrosis Hospitalized for an Acute Pulmonary Exacerbation

(2013) Jill M. Butterfield et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Microbial Persistence and the Road to Drug Resistance

(2013) Nadia R. Cohen et al.   Cell Host & Microbe

Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study

(2013) Heino Stass et al.   CLINICAL DRUG INVESTIGATION

Staphylococcus aureus Small-Colony Variants Are Independently Associated With Worse Lung Disease in Children With Cystic Fibrosis

(2013) Daniel J. Wolter et al.   CLINICAL INFECTIOUS DISEASES

Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial

(2013) Ivanka Galeva et al.   CURRENT MEDICAL RESEARCH AND OPINION

Panton-Valentine leukocidin (PVL) gene carriage among Staphylococcus aureus strains with SCCmec types I, III, IV, and V recovered from cystic fibrosis pediatric patients in Brazil

(2013) Danielle Ferreira Lima et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Diversity of  -lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study

(2013) C. Llanes et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antibiotic activity against small-colony variants of Staphylococcus aureus: review of in vitro, animal and clinical data

(2013) Laetitia G. Garcia et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and -resistant Pseudomonas aeruginosa

(2013) D. M. Hermes et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Antimicrobial susceptibility and molecular typing of MRSA in cystic fibrosis

(2013) E.A. Champion et al.   PEDIATRIC PULMONOLOGY

Phenotypic Heterogeneity of Pseudomonas aeruginosa Populations in a Cystic Fibrosis Patient

(2013) Matthew L. Workentine et al.   PLoS One

Evolutionary remodeling of global regulatory networks during long-term bacterial adaptation to human hosts

(2013) S. Damkiaer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Treatment of Pseudomonas andStaphylococcusBronchopulmonary Infection in Patients with Cystic Fibrosis

(2013) Rashmi Ranjan Das et al.   TheScientificWorldJOURNAL

Phase II studies of nebulised Arikace in CF patients withPseudomonas aeruginosainfection

(2013) J P Clancy et al.   THORAX

Antibiotic and Anti-Inflammatory Therapies for Cystic Fibrosis

(2013) J. F. Chmiel et al.   Cold Spring Harbor Perspectives in Medicine

The Cystic Fibrosis Airway Microbiome

(2013) S. V. Lynch et al.   Cold Spring Harbor Perspectives in Medicine

Aerosolised levofloxacin in cystic fibrosis

(2013) Gerd Döring et al.   Expert Opinion on Orphan Drugs

Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation

(2013) Katherine E Price et al.   Microbiome

In Vitro Antibiotic Susceptibility of Initial Pseudomonas aeruginosa Isolates From United States Cystic Fibrosis Patients

(2013) D. R. VanDevanter et al.   Journal of the Pediatric Infectious Diseases Society

Inhaled Aztreonam Lysine for Cystic Fibrosis Pulmonary Disease–Related Outcomes

(2012) Kimberly A Pesaturo et al.   ANNALS OF PHARMACOTHERAPY

Dosing Regimen Matters: the Importance of Early Intervention and Rapid Attainment of the Pharmacokinetic/Pharmacodynamic Target

(2012) Marilyn N. Martinez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Relative Contributions of Physical Structure and Cell Density to the Antibiotic Susceptibility of Bacteria in Biofilms

(2012) Amy E. Kirby et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The cystic fibrosis airway microbiome

(2012) Harvey R. Rabin et al.   CURRENT OPINION IN PULMONARY MEDICINE

Colistin: an update on the antibiotic of the 21st century

(2012) Silpak Biswas et al.   Expert Review of Anti-Infective Therapy

Resistance surveillance studies: a multifaceted problem—the fluoroquinolone example

(2012) A. Dalhoff   INFECTION

Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model

(2012) S. H. Zinner et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Evolution in Fast Forward: a Potential Role for Mutators in Accelerating Staphylococcus aureus Pathoadaptation

(2012) G. S. Canfield et al.   JOURNAL OF BACTERIOLOGY

A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis

(2012) Kavi J. Littlewood et al.   Journal of Cystic Fibrosis

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis

(2012) M.N. Hurley et al.   Journal of Cystic Fibrosis

The challenges and promises of new therapies for cystic fibrosis: Figure 1.

(2012) Gerald B. Pier   JOURNAL OF EXPERIMENTAL MEDICINE

Sub-lethal concentrations of antibiotics increase mutation frequency in the cystic fibrosis pathogenPseudomonas aeruginosa

(2012) C.G. Nair et al.   LETTERS IN APPLIED MICROBIOLOGY

In Vitro Antimicrobial Activity of “Last-Resort” Antibiotics Against Unusual Nonfermenting Gram-Negative Bacilli Clinical Isolates

(2012) Herve Jacquier et al.   Microbial Drug Resistance

Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones

(2012) Chris Stockmann et al.   PEDIATRIC PULMONOLOGY

The Adult Cystic Fibrosis Airway Microbiota Is Stable over Time and Infection Type, and Highly Resilient to Antibiotic Treatment of Exacerbations

(2012) Anthony A. Fodor et al.   PLoS One

Decade-long bacterial community dynamics in cystic fibrosis airways

(2012) J. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study

(2012) Antje Schuster et al.   THORAX

Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience

(2012) Franziska Anne Stressmann et al.   THORAX

Levofloxacin Inhalation Solution (MP-376) in Patients with Cystic Fibrosis withPseudomonas aeruginosa

(2011) David E. Geller et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

ComparativeIn VitroActivities of the Novel Antibacterial Finafloxacin against Selected Gram-Positive and Gram-Negative Bacteria Tested in Mueller-Hinton Broth and Synthetic Urine

(2011) Axel Dalhoff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dynamics of Mutator and Antibiotic-Resistant Populations in a Pharmacokinetic/Pharmacodynamic Model of Pseudomonas aeruginosa Biofilm Treatment

(2011) María D. Macià et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis Subjects

(2011) David E. Geller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Quantification of Amikacin in Bronchial Epithelial Lining Fluid in Neonates

(2011) C. Tayman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Recent advances in the treatment of Pseudomonas aeruginosainfections in cystic fibrosis

(2011) Niels Høiby   BMC Medicine

Colistin Penetration in the Alveolar Lining Fluid of Critically Ill Patients Treated With IV Colistimethate Sodium: Response

(2011) Roberto Imberti et al.   CHEST

Colistin Penetration in the Alveolar Lining Fluid of Critically Ill Patients Treated With IV Colistimethate Sodium

(2011) Nikolaos Markou et al.   CHEST

Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis

(2011) A. R. Hauser et al.   CLINICAL MICROBIOLOGY REVIEWS

Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective

(2011) Johan W. Mouton et al.   DRUG RESISTANCE UPDATES

Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia

(2011) G Christopher Wood   Expert Review of Anti-Infective Therapy

Spatial distribution of microbial communities in the cystic fibrosis lung

(2011) Dana Willner et al.   ISME Journal

Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ Technology

(2011) David E. Geller et al.   Journal of Aerosol Medicine and Pulmonary Drug Delivery

Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes

(2011) Evgeny A. Idelevich et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI)

(2011) C. M. Oermann et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Bacteriophages as vehicles of the resistome in cystic fibrosis

(2011) J. M. Rolain et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Heteroresistance to Cephalosporins and Penicillins in Acinetobacter baumannii

(2011) K.-H. Hung et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Staphylococcus aureus with decreased susceptibility to glycopeptides in cystic fibrosis patients

(2011) Anne Filleron et al.   Journal of Cystic Fibrosis

217* A multi-cycle open label study of nebulized liposomal amikacin (Arikace(tm)) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection

(2011) P. Minic et al.   Journal of Cystic Fibrosis

Review: Staphylococcus aureus and MRSA in cystic fibrosis

(2011) Christopher H. Goss et al.   Journal of Cystic Fibrosis

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa

(2011) C.E. Wainwright et al.   Journal of Cystic Fibrosis

Epistatic Roles for Pseudomonas aeruginosa MutS and DinB (DNA Pol IV) in Coping with Reactive Oxygen Species-Induced DNA Damage

(2011) Laurie H. Sanders et al.   PLoS One

Adaptive Evolution of Staphylococcus aureus during Chronic Endobronchial Infection of a Cystic Fibrosis Patient

(2011) Paul R. McAdam et al.   PLoS One

Positive Signature-Tagged Mutagenesis in Pseudomonas aeruginosa: Tracking Patho-Adaptive Mutations Promoting Airways Chronic Infection

(2011) Irene Bianconi et al.   PLoS Pathogens

Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronicPseudomonas aeruginosainfection in cystic fibrosis

(2011) Michael D Parkins et al.   Expert Review of Respiratory Medicine

Persister Cells

(2010) Kim Lewis   Annual Review of Microbiology

Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers

(2010) J. B. Bulitta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetic/Pharmacodynamic Investigation of Colistin against Pseudomonas aeruginosa Using an In Vitro Model

(2010) P. J. Bergen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance

(2010) A. Oliver et al.   CLINICAL MICROBIOLOGY AND INFECTION

The Changing Microbial Epidemiology in Cystic Fibrosis

(2010) J. J. LiPuma   CLINICAL MICROBIOLOGY REVIEWS

Methicillin resistance and vancomycin heteroresistance in Staphylococcus aureus in cystic fibrosis patients

(2010) V. Cafiso et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine

(2010) J Stuart Elborn et al.   EXPERT OPINION ON PHARMACOTHERAPY

Pseudomonas aeruginosabiofilms in cystic fibrosis

(2010) Niels Høiby et al.   Future Microbiology

Inhaled Anti-infective Agents: Emphasis on Colistin

(2010) A. Michalopoulos et al.   INFECTION

Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones

(2010) Axel Dalhoff et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Mutators in cystic fibrosis chronic lung infection: Prevalence, mechanisms, and consequences for antimicrobial therapy

(2010) Antonio Oliver   INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY

Adaptation of Staphylococcus aureus to the cystic fibrosis lung

(2010) Christiane Goerke et al.   INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY

Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?

(2010) D. Macdonald et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Characterization of macrolide resistance genes in Haemophilus influenzae isolated from children with cystic fibrosis

(2010) M. C. Roberts et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The Streptococcus milleri Population of a Cystic Fibrosis Clinic Reveals Patient Specificity and Intraspecies Diversity

(2010) C. D. Sibley et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

(2010) Michael W. Konstan et al.   Journal of Cystic Fibrosis

Community-acquired methicillin-resistant Staphylococcus aureus: community transmission, pathogenesis, and drug resistance

(2010) Tatsuo Yamamoto et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ciprofloxacin Hydrochloride

(2010) M.E. Olivera et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis andPseudomonas

(2010) Terry L. Noah et al.   PEDIATRIC PULMONOLOGY

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial

(2010) Michael W. Konstan et al.   PEDIATRIC PULMONOLOGY

An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

(2010) Christopher M. Oermann et al.   PEDIATRIC PULMONOLOGY

Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008

(2010) Julia Emerson et al.   PEDIATRIC PULMONOLOGY

Consensus Summary of Aerosolized Antimicrobial Agents: Application of Guideline Criteria

(2010) Jennifer Le et al.   PHARMACOTHERAPY

Airway Microbiota and Pathogen Abundance in Age-Stratified Cystic Fibrosis Patients

(2010) Michael J. Cox et al.   PLoS One

Quorum Sensing and Virulence of Pseudomonas aeruginosa during Lung Infection of Cystic Fibrosis Patients

(2010) Thomas Bjarnsholt et al.   PLoS One

Revealing the dynamics of polymicrobial infections: implications for antibiotic therapy

(2010) Geraint B. Rogers et al.   TRENDS IN MICROBIOLOGY

Nutrient Availability as a Mechanism for Selection of Antibiotic Tolerant Pseudomonas aeruginosa within the CF Airway

(2010) Lucas R. Hoffman et al.   PLoS Pathogens

Quorum Sensing Inhibition Selects for Virulence and Cooperation in Pseudomonas aeruginosa

(2010) Thilo Köhler et al.   PLoS Pathogens

Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infection

(2009) O. O. Okusanya et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Aerosol MP-376, a Levofloxacin Inhalation Solution, in Models of Mouse Lung Infection Due to Pseudomonas aeruginosa

(2009) M. Sabet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Pharmacodynamics of Levofloxacin and Other Aerosolized Antibiotics under Multiple Conditions Relevant to Chronic Pulmonary Infection in Cystic Fibrosis

(2009) P. King et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Elucidation of the Pharmacokinetic/Pharmacodynamic Determinant of Colistin Activity against Pseudomonas aeruginosa in Murine Thigh and Lung Infection Models

(2009) R. V. Dudhani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Resistance to Colistin in Acinetobacter baumannii Associated with Mutations in the PmrAB Two-Component System

(2009) M. D. Adams et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Small-Colony Variant Selection as a Survival Strategy for Staphylococcus aureus in the Presence of Pseudomonas aeruginosa

(2009) L. Biswas et al.   APPLIED AND ENVIRONMENTAL MICROBIOLOGY

Genomic analysis of an emerging multiresistant Staphylococcus aureus strain rapidly spreading in cystic fibrosis patients revealed the presence of an antibiotic inducible bacteriophage

(2009) Jean-Marc Rolain et al.   Biology Direct

Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis

(2009) George Z. Retsch-Bogart et al.   CHEST

A Long Journey from Minimum Inhibitory Concentration Testing to Clinically Predictive Breakpoints: Deterministic and Probabilistic Approaches in Deriving Breakpoints

(2009) A. Dalhoff et al.   INFECTION

Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis

(2009) M. I. Gillham et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis

(2009) D. L. MacLeod et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus

(2009) Harry Heijerman et al.   Journal of Cystic Fibrosis

Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations

(2009) J. L. Fothergill et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Effect of mutatorP. aeruginosaon antibiotic resistance acquisition and respiratory function in cystic fibrosis

(2009) Agnes Ferroni et al.   PEDIATRIC PULMONOLOGY

Extended-Interval Once-Daily Dosing of Aminoglycosides in Adult and Pediatric Patients with Cystic Fibrosis

(2009) William A Prescott et al.   PHARMACOTHERAPY

Aerosol Antibiotics in Cystic Fibrosis

(2009) David E Geller   Respiratory Care

Persistent Methicillin-resistantStaphylococcus aureusand Rate of FEV1Decline in Cystic Fibrosis

(2008) Elliott C. Dasenbrook et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Inhaled Aztreonam Lysine for Chronic AirwayPseudomonas aeruginosain Cystic Fibrosis

(2008) Karen S. McCoy et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

The Thymidine-Dependent Small-Colony-Variant Phenotype Is Associated with Hypermutability and Antibiotic Resistance in Clinical Staphylococcus aureus Isolates

(2008) S. Besier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effects of Antibiotics on Quorum Sensing in Pseudomonas aeruginosa

(2008) M. E. Skindersoe et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Complex Ciprofloxacin Resistome Revealed by Screening a Pseudomonas aeruginosa Mutant Library for Altered Susceptibility

(2008) E. B. M. Breidenstein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Complex Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus Isolates From Children With Cystic Fibrosis in the Era of Epidemic Community-Associated Methicillin-Resistant S aureus

(2008) Daniel Glikman et al.   CHEST

Pseudomonas aeruginosa diversity in distinct paediatric patient groups

(2008) G.A. Tramper-Stranders et al.   CLINICAL MICROBIOLOGY AND INFECTION

Efflux system overexpression and decreased OprD contribute to the carbapenem heterogeneity inPseudomonas aeruginosa

(2008) Alexandros Ikonomidis et al.   FEMS MICROBIOLOGY LETTERS

Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media

(2008) J. D. Perry et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

High prevalence in cystic fibrosis patients of multiresistant hospital-acquired methicillin-resistant Staphylococcus aureus ST228-SCCmecI capable of biofilm formation

(2008) A. Molina et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model

(2008) P. J. Bergen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Increased mutability of Pseudomonas aeruginosa in biofilms

(2008) K. Driffield et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A randomized placebo-controlled study of nebulized liposomal amikacin (Arikace™) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection

(2008) L. Dupont et al.   Journal of Cystic Fibrosis

Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme

(2008) Wing Yau et al.   JOURNAL OF INFECTION

Diffusible signals and interspecies communication in bacteria

(2008) R. P. Ryan et al.   MICROBIOLOGY-SGM

A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients

(2008) C. D. Sibley et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recurrent exacerbations affect FEV1 decline in adult patients with cystic fibrosis

(2008) Anna Amadori et al.   RESPIRATORY MEDICINE

Discerning the Complexity of Community Interactions Using a Drosophila Model of Polymicrobial Infections

(2008) Christopher D. Sibley et al.   PLoS Pathogens

Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis

(2007) Giuseppe Valenza et al.   Journal of Cystic Fibrosis